根据卫生委员会的说法，已经出现了一种双轨制，即能够负担数百英镑私立费用的人与无力负担的人之间存在差距。
A two-tier system has developed, according to the health committee, between those who can afford to pay hundreds of pounds privately and those who can't.
2026年10月23日星期五08:04，英国 议员们表示，推广减肥药“穆扎罗”的计划“缺乏雄心”，且覆盖的“人数少得可怜”。
Friday 23 October 2026 08:04, UK Plans for rolling out weight-loss drug Mounjaro are "unambitious" and will reach a "woefully small number of people", according to MPs.
他们表示，在国民保健署推出该药物的前三年里，只有6%的符合条件者将获得或目前正在获得该药物，而数百万民众则选择自费购买。
They say just 6% of those eligible will get - or currently receive - the drug in its first three years on the NHS, with millions buying it privately instead.
这一警告来自下议院卫生委员会，该委员会希望将肥胖症作为像糖尿病一样的长期和受控疾病来治疗。
The warning comes from the Commons' health committee, which wants obesity treated as a long-term and managed condition like diabetes.
“穆扎罗”（替尔泊肽）是最著名的GLP-1药物之一，与“韦戈维”和“欧霉派”齐名，通过每周注射一次的方式给药。它的作用机制是抑制食欲，并让人产生更长时间的饱腹感。
Mounjaro (tirzepatide) is one of the best known GLP-1 drugs, along with Wegovy and Ozempic, and is taken as a weekly injection. It works by suppressing appetite and making a person feel fuller for longer.
议员们表示，其推广速度需要大幅加快，因为在能够负担私立费用的人与无力负担的人之间，已经形成了一种“双轨制”。委员会敦促：“政府必须紧急重新评估‘穆扎罗’的推广步伐。”“这应当包括更好地利用数字服务提供商的承载能力。”
MPs say its rollout needs to be ramped up dramatically as a "two-tier system" has formed between those who can afford to pay privately and those who can't. "The government must urgently reassess the pace of rollout of Mounjaro," the committee urged. "This should include making better use of the capacity of digital providers.
“作为第一步，卫生部应与各大服务提供商和医疗保健专业人员举办一场关于GLP-1获取途径的峰会，就如何最好地改进推广工作开启对话。”英国国家健康与护理卓越研究所于2024年6月推荐使用“穆扎罗”来治疗肥胖症。“韦戈维”（司美格鲁肽）也已获得国民保健署的批准。
"As a first step, the department should hold a summit on GLP-1 access with a range of providers and healthcare professionals to open a dialogue on how best to improve the rollout." The National Institute for Health and Care Excellence (Nice) recommended Mounjaro to treat obesity in June 2024. Wegovy (semaglutide) has also been approved by the NHS.
国民保健署估计，如果所有人在该药物上市的第一年都申请使用，五年内将有280万人符合使用“穆扎罗”的条件，耗资152亿英镑。
The NHS estimated 2.8 million people would be eligible for Mounjaro, at a cost of £15.2bn over five years, if all signed on for the drug in its first year of availability.
健康与护理卓越研究所同意了英国国民保健署逐步引入的要求，最终决定在三年内仅向22万名患者推广。
Nice agreed to NHS England's request to introduce it gradually instead, and it's only being rolled out to 220,000 over three years.
议员们的报告呼吁建立一个新的框架，“为当地人口中能够获得GLP-1药物的比例设定宏伟的目标”。
The MPs' report calls for a new framework to "include ambitious targets for the proportion of a local population that should be able to access GLP-1s".
报告称，英国每个月开出约240万盒GLP-1药物处方，但绝大多数都是自费购买的。
It says around 2.4 million packs of GLP-1 drugs are prescribed each month in the UK but the vast majority are being bought privately.
一个月剂量的“穆扎罗”价格从最低剂量的约150英镑到最高剂量的约350英镑不等。
Prices for a month's supply of Mounjaro range from about £150 for the smallest dose to about £350 for the highest.
全科医生诊所将因开具减肥注射剂而获得3000英镑奖金 “穆扎罗”和“韦戈维”可能“需要终身使用” 议员们警告称：“获取GLP-1药物似乎越来越多地由支付能力而非临床需求决定。”
GP practices to be offered £3,000 bonus for prescribing weight-loss jabs Mounjaro and Wegovy 'may need to be continued for life' "Access to GLP-1 medication appears increasingly to be determined by ability to pay rather than clinical need," the MPs warn.
“鉴于肥胖症本就伴随着明显的剥夺和不平等分界线，若无法提供公平的获取途径，将巩固并扩大这些差距，辜负那些最需要支持的患者。”
"Given that obesity already follows stark lines of deprivation and inequality, failing to provide equitable access will entrench and widen those disparities, letting down the patients who need support most."
国民保健署发言人表示，该机构正在“测试加速获取的新方法，包括使用这些药物的新途径”。
An NHS spokesperson said it was "testing new ways to accelerate access, including new routes for starting these medicine".
发言人称，针对肥胖症的“广泛其他支持”也已到位，“这些支持已经帮助数万名民众实现了更健康的体重”。
It said "a wide range of other support" for obesity was also available, "which has already helped tens of thousands of people achieve a healthier weight".